Clinical Report: CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
Overview
A single infusion of CD19 CAR T cells reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis. Follow-up periods ranged from 36 to 52 weeks.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that can lead to significant morbidity and disability. Traditional treatments often fail in patients with refractory disease.
Data Highlights
| Parameter | Result |
|---|---|
| Median disease activity score reduction at week 24 | 49% |
| Median disease activity score reduction at latest follow-up | 34% |
| Participants achieving clinical remission | 4 |
| Participants maintaining remission without medication | 3 |
| Decline in anti-mutated citrullinated vimentin antibodies | 94% |
Key Findings
- All six participants experienced a reduction in disease activity scores.
- Three participants maintained remission without disease-modifying drugs or glucocorticoids.
- Grade 1 or 2 cytokine release syndrome occurred in all participants but resolved after treatment.
- Four participants became seronegative for rheumatoid arthritis-associated autoantibodies.
- No severe adverse events were reported during the study.
Clinical Implications
Further research is needed to evaluate the long-term safety and efficacy of CD19 CAR T cell therapy in patients with refractory rheumatoid arthritis.
Conclusion
This initial trial indicates that CD19 CAR T therapy may reduce disease activity in severe rheumatoid arthritis.
Related Resources & Content
- MDSpire News, 2025 -- CD19 CAR T-Cell Therapy in Patients With Autoimmune Disease
- the asco post, 2025 -- CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis
- the asco post, 2025 -- Enhanced CAR T-Cell Therapy for Lymphoma After Previous Failure on CAR T-Cell Therapy
- Recommendations Management | EULAR, 2026 -- EULAR Recommendations Management
- CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial, Nature Medicine, 2026
- the asco post — Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma
- Recommendations Management | EULAR
- CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial | Nature Medicine
- CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
